insights_auto
Outlook: 62.2% bullish·2.2% bearish
Go to analysischevron_right
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$735.20
arrow_upward
+0.05%(+0.39) 1D
$735.20
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 2, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
$740.50
High
$742.50
Low
$729.20
Mkt. cap
75.69B
Avg. vol.
723.86K
Volume
613.95K
Dividend
0.51%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.18
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
Open
$740.50
High
$742.50
Low
$729.20
Mkt. cap
75.69B
Avg. vol.
723.86K
Volume
613.95K
Dividend
0.51%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.18
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
AD HOC NEWS
·
8 minutes ago
Sanofi stock falls 3.13 percent after Regeneron deal expands pipeline costs
The Globe and Mail
·
7 hours ago
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN)
Simply Wall Street
·
7 hours ago
Regeneron Pharmaceuticals (REGN) Could Be 14% Undervalued Following $1b Sanofi Alliance Expansion
The Globe and Mail
·
8 hours ago
Regeneron (REGN) Gets a Hold from Scotiabank
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com